NCT06164717 Behavioral and Neural Characteristics of Adaptive Speech Motor Control
| NCT ID | NCT06164717 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Speech |
| Study Type | INTERVENTIONAL |
| Enrollment | 507 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 507 participants in total. It began in 2023-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study meets the NIH definition of a clinical trial, but is not a treatment study. Instead, the goal of this study is to investigate how hearing ourselves speak affects the planning and execution of speech movements. The study investigates this topic in both typical speakers and in patients with Deep Brain Stimulation (DBS) implants. The main questions it aims to answer are: * Does the way we hear our own speech while talking affect future speech movements? * Can the speech of DBS patients reveal which brain areas are involved in adjusting speech movements? Participants will read words, sentences, or series of random syllables from a computer monitor while their speech is being recorded. For some participants, an electrode cap is also used to record brain activity during these tasks. And for DBS patients, the tasks will be performed with the stimulator ON and with the stimulator OFF.
Eligibility Criteria
General inclusion criteria: * native speaker of American English * no communication or neurological problems (except for subjects in the DBS group) * 250-4000 Hz pure tone hearing thresholds equal to or better than 25 dB HL for children and young adults and equal to or better than 35 dB HL for older adults * no medications that affect sensorimotor functioning (except for in the DBS group) * adult subjects: 18 years of age or older * typical children: 4;0 to 6;11 \[years;months\] or 10;0 to 12;11 \[years;months\]) Specific inclusion criteria for children: \* scoring above the 20th percentile on the Peabody Picture Vocabulary Test (PPVT-5), Expressive Vocabulary Test (EVT-3), Goldman-Fristoe Test of Articulation (GFTA-3), and either Test of Early Language Development (TELD-4) or (for children age 8 or older) Clinical Evaluation of Language Fundamentals (CELF-5). Specific inclusion criteria for DBS patients: \* bilateral electrodes implanted in either the ventral intermediate nucleus of the thalamus (Vim; a target site for patients with essential tremor) or subthalamic nucleus (STN; a target site for patients with Parkinson's disease)
Contact & Investigator
Ludo Max, Ph.D.
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT06164717 clinical trial?
This trial is open to participants of all sexes, aged 4 Years or older, studying Speech. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06164717 currently recruiting?
Yes, NCT06164717 is actively recruiting participants. Contact the research team at ludomax@uw.edu for enrollment information.
Where is the NCT06164717 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT06164717 clinical trial?
NCT06164717 is sponsored by University of Washington. The principal investigator is Ludo Max, Ph.D. at University of Washington. The trial plans to enroll 507 participants.